Monitra Health Secures New Funding as upBeat Establishes itself as a Global Cardiac Monitoring Leader

Since its previous funding round in December 2023, Monitra has transformed from a company with potential to a recognized leader in the field.

Monitra Health, the medtech company behind the upBeat cardiac monitoring platform, has successfully closed a new funding round led by IAN Group, with contributions from New Age India Fund, Lavni Ventures, VCMint, Global HealthX, and notable healthcare investors, including Dr. Ramesh Kancherla.

This latest funding reflects a strong vote of confidence in Monitra's clinical advancements and global aspirations.

“Our last round was about proving this could work. This one is about proving it can work everywhere. Crossing 50,000 patients, analyzing over 10 billion heartbeats, and growing revenue 11x has moved upBeat® from a promising platform to an indispensable one for a growing number of clinicians. We are grateful to this set of investors for backing that future with us,” Ravi Bhogu, Founder & CEO, Monitra Health.

Since its previous funding round in December 2023, Monitra has transformed from a company with potential to a recognized leader in the field. The upBeat platform has scaled remarkably, now monitoring over 50,000 patients, a fivefold increase from the previous 10,000, demonstrating significant hospital integration and growing adoption among healthcare providers.

With more than 10 billion heartbeats analyzed, Monitra boasts one of the largest proprietary datasets of high-resolution continuous ECG data in the industry. In the past four years, the company has witnessed an impressive 11-fold increase in revenue, driven by strategic execution and a growing base of prescribing clinicians.

Major hospital networks, including Manipal, Apollo, Aster, and AIG, have placed their trust in upBeat, expanding its reach across Tier 1 to Tier 4 cities in India.

The remote cardiac monitoring industry is expected to expand from USD 4.1 billion in 2024 to USD 12 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 11.3%. Monitra stands out as one of the few companies globally to provide a comprehensive full-stack solution, encompassing device and signal-acquisition technology, clinical reporting workflows, and advanced analytics, significantly enhancing diagnostic precision and scalability through proprietary technologies like XtremeSpan, NanoVue, and DeepFind.

“We first backed Monitra when the thesis was still being tested. Doubling down today is one of the easier decisions we have made — the clinical footprint has scaled 5x, revenue has grown 11x, the IP has deepened, and the team has stayed remarkably disciplined with capital. Monitra has exactly the kind of deep-tech healthcare solutions India should be exporting to the world,” Vasu Guruswamy, Co-founder & General Partner, Lavni Ventures.

The upBeat platform offers continuous monitoring that captures arrhythmic events often missed by short-duration tests, thereby improving diagnostic yields and patient outcomes.

Looking ahead, Monitra Health is poised for an exciting growth phase, marked by strong clinical validation, expanding international regulatory pathways, and a commitment to enhancing its global footprint. The company's focus will be on accelerating global certifications and scaling its commercial operations within India while deepening its clinical and organizational capabilities.

“We are truly upBeat about our investment in Monitra Health. It is rare to find a company that combines strong IP, patented technology, cost advantage, and a world-class product built in India for global markets. With growing adoption among leading hospitals and cardiologists, Monitra has demonstrated both innovation and execution. We believe the company has the potential to become a global leader in cardiac monitoring - from India to the world,” Avinash Kalia, New Age India Fund.

Stay tuned for more such updates on Digital Health News